Characteristics of patients identified with SMN after treatment on ALL-BFM trials 79 to 2000 and included in thiopurine methyltransferase genotype analyses in comparison with SMN patients not included
| . | SMN patients included in genotyping (n = 105), n (%) . | SMN patients not included in genotyping (n = 24), n (%) . | P‡ . |
|---|---|---|---|
| Sex | |||
| Male | 65 (61.9) | 13 (54.2) | |
| Female | 40 (38.1) | 11 (45.8) | .489 |
| Age at diagnosis, y | |||
| < 1-6 | 72 (68.6) | 15 (62.5) | |
| > 6 | 33 (31.4) | 9 (37.5) | .328 |
| Initial WBC, /μL | |||
| < 10 000 | 45 (42.9) | 11 (45.8) | |
| ≥ 10 000-<50 000 | 34 (32.4) | 10 (41.7) | |
| ≥ 50 000 | 12 (11.4) | 1 (4.2) | |
| ≥ 100 000 | 14 (13.3) | 2 (8.3) | .583 |
| Immunophenotype | |||
| B | 70 (66.7) | 19 (79.2) | |
| T | 26 (24.8) | 3 (12.5) | .273 |
| Other/not characterized | 9 (8.6) | 2 (8.3) | |
| BFM study | |||
| ALL-BFM 79 | 4 (3.8) | ||
| ALL-BFM 81 | 14 (13.3) | 1 (4.2) | |
| ALL-BFM 83 | 8 (7.6) | ||
| ALL-BFM 86 | 15 (14.3) | 2 (8.3) | |
| ALL-BFM 90 | 26 (24.8) | 12 (50.0) | |
| ALL-BFM 95 | 27 (25.7) | 4 (16.7) | |
| ALL-BFM 2000 | 11 (10.5) | 5 (20.8) | .080 |
| Cranial irradiation | |||
| No | 39 (37.1) | 9 (37.5) | |
| Yes | 66 (62.9) | 15 (62.5) | .999 |
| Risk group* | |||
| Standard | 38 (37.6) | 4 (16.7) | |
| Intermediate | 52 (51.5) | 17 (70.8) | |
| High | 11 (10.9) | 3 (12.5) | .143 |
| SMN† | |||
| Hematologic | 60 (57.1) | 8 (37.0) | |
| Brain tumor | 21 (20.0) | 11 (40.7) | |
| Other solid tumors | 24 (22.9) | 5 (22.2) | .025 |
| Median time to SMN, y | |||
| < 3 | 33 (31.4) | 3 (12.5) | |
| ≥ 3-<10 | 56 (53.3) | 14 (58.3) | |
| ≥ 10 | 16 (15.2) | 7 (29.2) | .094 |
| . | SMN patients included in genotyping (n = 105), n (%) . | SMN patients not included in genotyping (n = 24), n (%) . | P‡ . |
|---|---|---|---|
| Sex | |||
| Male | 65 (61.9) | 13 (54.2) | |
| Female | 40 (38.1) | 11 (45.8) | .489 |
| Age at diagnosis, y | |||
| < 1-6 | 72 (68.6) | 15 (62.5) | |
| > 6 | 33 (31.4) | 9 (37.5) | .328 |
| Initial WBC, /μL | |||
| < 10 000 | 45 (42.9) | 11 (45.8) | |
| ≥ 10 000-<50 000 | 34 (32.4) | 10 (41.7) | |
| ≥ 50 000 | 12 (11.4) | 1 (4.2) | |
| ≥ 100 000 | 14 (13.3) | 2 (8.3) | .583 |
| Immunophenotype | |||
| B | 70 (66.7) | 19 (79.2) | |
| T | 26 (24.8) | 3 (12.5) | .273 |
| Other/not characterized | 9 (8.6) | 2 (8.3) | |
| BFM study | |||
| ALL-BFM 79 | 4 (3.8) | ||
| ALL-BFM 81 | 14 (13.3) | 1 (4.2) | |
| ALL-BFM 83 | 8 (7.6) | ||
| ALL-BFM 86 | 15 (14.3) | 2 (8.3) | |
| ALL-BFM 90 | 26 (24.8) | 12 (50.0) | |
| ALL-BFM 95 | 27 (25.7) | 4 (16.7) | |
| ALL-BFM 2000 | 11 (10.5) | 5 (20.8) | .080 |
| Cranial irradiation | |||
| No | 39 (37.1) | 9 (37.5) | |
| Yes | 66 (62.9) | 15 (62.5) | .999 |
| Risk group* | |||
| Standard | 38 (37.6) | 4 (16.7) | |
| Intermediate | 52 (51.5) | 17 (70.8) | |
| High | 11 (10.9) | 3 (12.5) | .143 |
| SMN† | |||
| Hematologic | 60 (57.1) | 8 (37.0) | |
| Brain tumor | 21 (20.0) | 11 (40.7) | |
| Other solid tumors | 24 (22.9) | 5 (22.2) | .025 |
| Median time to SMN, y | |||
| < 3 | 33 (31.4) | 3 (12.5) | |
| ≥ 3-<10 | 56 (53.3) | 14 (58.3) | |
| ≥ 10 | 16 (15.2) | 7 (29.2) | .094 |
WBC indicates white blood cell count.
Because there were only 2 risk groups, patients from ALL-BFM 79 were not included.
Specific diagnoses of included SMN were as follows: hematologic SMN: Hodgkin lymphoma (n = 5), non-Hodgkin lymphoma (n = 5), malignant histiocytosis (n = 5), ALL (n = 2), AML/MDS (n = 41), and CML (n = 2); brain tumors: primitive neuroectodermal tumor of CNS (n = 4), meningeoma (n = 2), astrocytoma (n = 5), glioblastoma (n = 8), gliosarcoma (n = 1), and oligodendroglioma (n = 1); other solid tumors: thyroid cancer (n = 2), Ewing sarcoma/peripheral primitive neuroectodermal tumor (n = 9), basal cell carcinoma (n = 2), epithelial carcinoma (n = 2), mucoepidermoid carcinoma (n = 1), malignant teratoma (n = 2), melanoma (n = 2), nephroblastoma (n = 1), osteosarcoma (n = 1), synovial sarcoma (n = 1), and unknown secondary tumor with lung metastasis (n = 1).
P value by χ2 or Fisher exact test.